A Phase IIb, 4 Arm Open-label, Randomized Trial, to Assess the Safety and Efficacy of Concurrent hR3 Monoclonal Antibody against EGF-receptor with Chemoradiation Therapy or with Radiation Therapy in Patients with Advanced (Stage III–IVa), Inoperable Head and Neck Cancer

Viswanath, Lokesh; Reddy, Krishna; Vidyasagar, M S; Koteshwar, Reshma; Shenoy, Anil; Naveen, T; Babu, Govind; Joseph, Bindhu; Bapsy, P P

doi:10.1016/j.ijrobp.2009.07.059

International Journal of Radiation Oncology*Biology*Physics

2009

DOI: 10.1016/j.ijrobp.2009.07.059

|View full text |Cite

A Phase IIb, 4 Arm Open-label, Randomized Trial, to Assess the Safety and Efficacy of Concurrent hR3 Monoclonal Antibody against EGF-receptor with Chemoradiation Therapy or with Radiation Therapy in Patients with Advanced (Stage III–IVa), Inoperable Head and Neck Cancer

Lokesh Viswanath¹,

Krishna Reddy²,

M S Vidyasagar³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A Phase IIb, 4 Arm Open-label, Randomized Trial, to Assess the Safety and Efficacy of Concurrent hR3 Monoclonal Antibody against EGF-receptor with Chemoradiation Therapy or with Radiation Therapy in Patients with Advanced (Stage III–IVa), Inoperable Head and Neck Cancer

Cited by 2 publications

References 0 publications

A network meta-analysis of the sequencing and types of systemic therapies with definitive radiotherapy in locally advanced squamous cell carcinoma of the head and neck (LASCCHN)☆

A network meta-analysis of the sequencing and types of systemic therapies with definitive radiotherapy in locally advanced squamous cell carcinoma of the head and neck (LASCCHN)☆

Retrospective analysis to assess the feasibility of escalated dose of nimotuzumab in patients with locally advanced head and neck cancer

Contact Info

Product

Resources

About